Ocean Biomedical
Ocean Biomedical is a 21st century biopharma company that partners with leading scientists and research institutions to accelerate the translation of new discoveries into breakthrough medicines. We`re working to bring together the interdisciplinary expertise and resources required to develop a diverse portfolio of pharmaceutical inventions and technologies through preclinical, clinical, and commercial development. We aim to build a continuous pipeline of drug development opportunities through our relationships with universities and medical centers. Every day we have one thing on our minds, getting safe, effective, medicines to the doctors and patients who need them most, all around the world.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical / Health Care - Pharmaceuticals
- Market Focus:
- Globally (various continents)
About us
Our current product candidates are licensed from Brown University, Stanford University, and Rhode Island Hospital. Our pipeline consists of both preclinical and clinical-stage programs. We anticipate moving certain preclinical product candidates in our oncology, fibrosis and/or infectious disease platforms, into the clinic in the next 12 to 18 months. We also expect that our anti-inflammatory product candidates licensed from Stanford, will commence Phase 1 clinical trials for the treatment of symptoms of COVID-19, in the first quarter of 2021.
Our programs in oncology and fibrosis are based on discoveries of disease pathways and of related drug targets emerging from pioneering work in the field of chitinase biology by our scientific co-founder, Jack A. Elias, M.D., Dean of Medicine at Brown.
In infectious disease we are developing therapeutic and vaccine candidates against malaria, a disease that kills 500,000 children under the age of five globally each year, that infects 200-300 million people annually worldwide, and for which 3.4 billion people worldwide are at risk. Our product candidates in malaria are based on the discovery by Jonathan Kurtis, M.D., Ph.D., Chair of Pathology and Laboratory Medicine and Director of the M.D./Ph.D. Program at Brown, of two novel malaria antigens, PfSEA-1 and PfGARP which have shown a significant reduction in malaria parasites under testing (press links below).
Ocean Biomedical is partnering with top tier researchers to accelerate new discoveries in the world of medicine, one powerful idea at a time.
Approach
Empowering Great Science. Accelerating Translation. Changing Medicine.
Ocean Biomedical is building innovative partnerships with promising researchers and institutions. Together we identify medical discoveries that can change global health outcomes.
We deploy the funding and expertise to move new therapies efficiently from the laboratory to the clinic, to the world.
Today, cutting-edge research by emerging scientists is yielding powerful new discoveries at universities all over the world, channeling billions of dollars a year in research grants in the U.S. alone. Through unique partnership vehicles, Ocean Biomedical works with scientists and their host institutions to accelerate promising innovations, and advance them as efficiently as possible, from bench to bedside. We work to allocate the funding and expertise necessary to turn ideas into realities, one great discovery at a time.
Every medical breakthrough begins with an idea, but translating even the best ideas into reality is a complex and challenging process. When Ocean Biomedical’s acquisition team identifies a research asset for acceleration, everything changes.
We back our partner-researchers with an experienced development team, with insights into every phase of biopharmaceutical development. We identify the most efficient pathway through the preclinical phase, through each tier of trials and approvals, and on to manufacturing, and distribution.
We put the financial and managerial backing in place to allow talented researchers to focus on developing amazing science. And that enables us to get new medicines to the doctors and patients who need them, as quickly and efficiently as possible.
Our mission is to solve the 21st century’s most intractable health problems, no matter how big or small.
All of the easy problems have been solved.
It’s time for a new way of thinking.
We're backing a new generation of scientists who are bringing new perspectives to the most complex problems facing medicine and society today. Our scientists are uncovering medical possibilities by thinking different, and our development team is using fresh, new approaches to help turn dreams into reality and improve people’s lives in every corner of the world.
Partnerships
Building Powerful Partnerships For Powerful Medicine
Promising science needs strong backing to move forward. We work with individual scientists and innovative research institutions to keep great discoveries moving through the toughest phases of the research pipeline.
We’re finding innovative pre-clinical research, then partnering with scientists to turn promising inventions into clinical ready assets, one great discovery at a time.
In 2021, great science is almost always born in an environment that fosters strong collaboration. Our experience tells us that great science tends to cluster: within groundbreaking labs, within departments that push boundaries, within universities that are powerfully led. Our unique partnership model allows universities and research institutes to set up long term backing that can accelerate promising discoveries and keep research funds cycling.
Leading Science
We identify science that has the potential to shake things up, approaching entrenched problems in a whole new way. We put our support behind new ideas that are going to matter, for individuals and whole societies.
Ocean Biomedical is currently developing five promising discoveries that have potential to make major changes in lung cancer care, pulmonary fibrosis, and the prevention and treatment of malaria.
We’re working on solving some of the toughest problems, for the people who need it most.
FOCUSED ON PROGRESS
Great research science happens in small, incremental steps that require patience, tenacity, and strong backing. At each step in the process, we work to remove obstacles, allowing our scientists to focus on what they do best. From preclinical work to clinical trials and into commercial development, our experienced team smooths the road to create real progress.
PULMONARY FIBROSIS
A new pathway to treating pulmonary fibrosis.
We’re working on a new approach to treating Idiopathic Pulmonary Fibrosis, focusing on manipulating enzymes in ways that have been shown to have minimal system toxicity.
The background research for this asset has not yet been disseminated publicly and is currently in the pre-clinical stage, preparing for Phase 1 trials.
MALARIA VACCINE
For 500,000 children and their families each year, a malaria vaccine is life or death.
Malaria is one of the most devastating diseases in human history, and one of the most intractable diseases in modern times. It is the largest killer of children under 5 years old. And its long-term effects ruin lives and hold back societies.
We’re working to change that, with a novel approach to breaking the malarial cycle. Starting with an examination of the differences between healthy and sick children in sub-Saharan Africa, our scientists have discovered 3 distinct antibodies that can be used to create a revolutionary vaccine, and a novel treatment approach.